Increased exposure w/ strong CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole, & grapefruit or grapefruit juice); moderate CYP3A4 inhibitors (eg, aprepitant, ciprofloxacin, conivaptan, crizotinib, cyclosporine, diltiazem, dronedarone, erythromycin, fluconazole, fluvoxamine, grapefruit juice, imatinib, isavuconazole, tofisopam & verapamil); OATP2B1 inhibitors. Decreased exposure w/ strong CYP3A4 inducers (eg, phenytoin, rifampicin, carbamazepine & St. John's wort); moderate CYP3A4 inducers (eg, bosentan, cenobamate, dabrafenib, efavirenz, etravirine, lorlatinib, phenobarb, primidone & sotorasib). Increased exposure of digoxin & other P-gp substrates; rosuvastatin & other BCRP substrates.
Sign Out
